MarketExclusive.com – Maxim Group Reiterates BUY Rating for Matinas BioPharma Holdings, Inc. and Provides Company Update

NEW YORK, NY / ACCESSWIRE / October 5, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) with a 12-month price target of $6.00 per share. The analyst note was published following the announcement that Matinas has received IRB approval to commence a NIH-Sponsored Phase 2a study with MAT2203.

Recent Matinas BioPharma Company Highlights:

– Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 – An Orally Delivered, Encochleated Formulation of Amphotericin B –

– Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 – Encochleated Amikacin – Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015

– Matinas BioPharma’s MAT2203 — Encochleated Formulation of Amphotericin B — Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015

– Matinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA

About Market Exclusive

Market Exclusive is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

SOURCE: Market Exclusive

ReleaseID: 432460